feed

view company updates

tools

perform investment research

network

join events & discussions

advisory

about us

Redeye Capital

Irlab Therapeutics Q4’20: Vår kommentar

Research Note

2021-02-24

09:08

Redeye ger sin kommentar till Irlabs delårsrapport för det fjärde kvartalet.

AH

Anders Hedlund

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.